Evaluating Benralizumab Treatment in Adults with Severe Asthma and Allergic Bronchopulmonary Aspergillosis A Real-World Prospective Study on Effectiveness and Safety

What this Trial Is About

Researchers are evaluating the effects of benralizumab in treating patients with severe asthma complicated by allergic bronchopulmonary aspergillosis ABPA. This open-label study aims to assess the real-world effectiveness and safety of benralizumab for this condition, focusing on reducing asthma exacerbations requiring steroids and improving patient quality of life. Participants will receive benralizumab injections every 4 weeks for the first three doses, followed by a fourth injection given eight weeks later, totaling 16 weeks of active treatment. After completing treatment, participants will have a follow-up visit eight weeks after the last injection, with the studys termination visit occurring at week 24. During the study, participants will have their asthma exacerbations requiring steroids tracked over 26 weeks as the primary outcome. Secondary outcomes include quality of life measured by the Saint George Respiratory Questionnaire, asthma control assessed by the Asthma Control Questionnaire 6, and lung function evaluated by FEV1. Participants who discontinue early will complete the termination procedures. The total study participation lasts approximately 24 weeks from the first treatment dose.

Real-World Effectiveness of Benralizumab in Allergic Bronchopulmonary Aspergillosis